<DOC>
	<DOCNO>NCT03005964</DOCNO>
	<brief_summary>To compare safety efficacy profile AM001 Cream , 7.5 % vehicle cream treatment plaque psoriasis</brief_summary>
	<brief_title>Safety Efficacy Study Comparing AM001 Cream , 7.5 % Vehicle Cream Treatment Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Subjects must provide write informed consent . 2 . Subjects must male female , least 18 year age . 3 . Subjects definite diagnosis plaque psoriasis clinically active ( least 3 month ) , involve least 10 % 20 % body surface area ( include head [ scalp , face ] , hand , foot , intertriginous area ) . 4 . Subjects Investigator 's Global Assessment ( IGA ) disease severity least moderate severity ( score ≥ 3 ) overall assessment . 5 . Subjects target lesion follow characteristic : 1. locate extremity ( i.e. , arm legs ) area ≥25 cm2 ; 2. minimum plaque erythema least moderate severity ( PASI grade ≥ 3 ) ; 3. minimum plaque scale severity least moderate severity ( PASI grade ≥ 3 ) ; 4. minimum plaque elevation least moderate severity ( PASI grade ≥ 3 ) ; 6 . If female childbearing potential , subject must negative urine pregnancy test , must use acceptable form birth control least two month prior Visit 1/Screening willing continue birth control throughout study . 7 . Subjects must willing able understand comply requirement study , apply assigned investigational product instruct , return require treatment period visit , comply therapy prohibition , able complete study . 8 . Subjects must good health , confirm medical history physical exam , free clinically significant disease/condition , plaque psoriasis , might interfere study evaluation . 9 . Subjects must willing limit sun exposure overall . Subjects prohibit sunbathe intentional tanning intense sun exposure include use tan booths/lights artificial UV light source throughout study . 1 . Female subject pregnant , nursing , plan pregnancy within study participation period . 2 . Subjects current diagnosis guttate , pustular , inverse , exfoliative , erythrodermic psoriasis . 3 . Subjects history psoriasis unresponsive topical treatment . 4 . Subjects history disorder may interfere evaluation plaque psoriasis ( e.g. , atopic dermatitis , contact dermatitis , tinea corporis , cutaneous lymphoma , etc. ) . 5 . Presence pigmentation , extensive scarring , pigmented lesion treatment area , could interfere rating efficacy parameter . 6 . Subjects unstable medical disorder , lifethreatening disease , current malignancy . 7 . Subjects clinically significant ECG laboratory abnormality Visit 1/Screening ( determine Principal Investigator designee ) . 8 . Subjects immunosuppressed . 9 . Subjects history allergy know hypersensitivity component investigational product . 10 . Subjects treat systemic steroid within 4 week prior study entry ( intranasal inhale corticosteroid acceptable keep constant throughout study , intraarticular steroid injection permissible ) . 11 . Subjects treat systemic photo antipsoriatic therapies/drugs within 4 week prior study entry include methotrexate , cyclosporine , acitretin oral retinoids , broadband narrowband UVB , PUVA , home professional tan light nonprescription UV light source , photodynamic therapy ( PDT ) , laser , mycophenalate mofetil ( MMF ) , thioguanine , hydroxyurea , sirolimus , azathioprine , 6mercaptopurine ( 6MP ) , etanercept . 12 . Subjects treat biologic therapy etanercept within 8 week prior study entry , include adalibumab , infliximab , ustekinumab , golimumab , rituximab . Vaccines consider exclusionary biologic treatment . 13 . Subjects treat biologic agent list psoriasis psoriatic arthritis within 12 week . 14 . Subjects treat topical antipsoriatic ( e.g. , salicylic acid , anthralin , tar , etc. , ) topical corticosteroid medication , topical retinoids ( e.g. , tazarotene , tretinoin ) , topical Vitamin D analog ( e.g. , calcipotriene ) , topical immunosuppressant ( e.g. , tacrolimus , pimecrolimus ) within 2 week prior study entry . 15 . Subjects treat lithium , antimalarial agent , quinidine within 4 week prior study entry . 16 . Subjects receive radiation therapy and/or antineoplastic agent , take immunosuppressant medication within 3 month prior study entry . 17 . Subjects consume excessive amount alcohol , abuse drug , condition would compromise compliance , investigator 's opinion , protocol . 18 . Subjects treat investigational drug investigational device within period 30 day prior study entry , within 120 day investigational biologic agent . 19 . Subjects previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>